natgillin/translations-raw huggingface dataset:
JuniorSTAR which delivers Insuman Comb 50 in 0.5 unit dose increments
JuniorSTAR, s katerim odmerjamo zdravilo Insuman Comb 50 z odmerki po 0,5 enot
JuniorSTAR which delivers Insuman Rapid in 0.5 unit dose increments
JuniorSTAR, s katerim odmerjamo zdravilo Insuman Rapid z odmerki po 0,5 enot
JuniorSTAR which delivers Lantus in 0.5 unit dose increments
JuniorSTAR, s katerim odmerjamo zdravilo Lantus z odmerki po 0,5 enot
JuniorSTAR which delivers Toujeo in 0.5 unit dose increments
JuniorSTAR, s katerim odmerjamo zdravilo Toujeo z odmerki po 0,5 enot
Just after an injection, your muscles may feel tense or very weak – as though you are having a relapse.
Takoj po injiciranju boste morda občutili napetost ali izjemno slabotnost v mišicah – kot da se je bolezen ponovila.
Just before drawing into the syringe, the vial should be agitated to re-suspend the microbubbles.
Neposredno pred odvzetjem z injekcijsko brizgo, moramo vialo pretresti, da ponovno nastane disperzija mikromehurčkov.
Just before use, roll the long–acting (cloudy) insulin between your hands until the liquid is uniformly white and cloudy.
Dolgodelujoči (motni) insulin tik pred uporabo zavrtite med dlanmi, dokler ni tekočina enakomerno bela in motna.
Just before withdrawing DepoCyte, the vial should be gently inverted to mix the particles evenly.
Tik preden odvzamete zdravilo DepoCyte, nežno obrnite vialo, da enakomerno pomešate delce.
Just before you start to inhale, break the glass ampoule containing 1 ml solution, which has two coloured rings (white - yellow), and pour the complete contents into the nebuliser medication chamber.
Tik pred začetkom inhaliranja prelomite stekleno ampulo, ki vsebuje 1 ml raztopine in je označena z dvema barvnima obročema (bel-rumen) in celotno vsebino zlijte v prostor za zdravilo v nebulatorju.
Just before you start to inhale, take the yellow-red colour coded ampoule of
Tik pred začetkom inhaliranja vzemite ampulo rumeno-rdeče barve zdravila Ventavis
Just take your next dose at the usual time.
Naslednji odmerek uporabite ob običajnem času.
Just take your next dose at the usual time.
Preprosto uporabite naslednji odmerek ob običajnem času.
Just take your normal dose at the usual time the next day.
Vzemite normalni odmerek ob običajnem času naslednji dan.
Just taking Truvada may not stop you getting HIV.
Samo jemanje zdravila Truvada morda ne bo preprečilo okužbe s HIV.
Justification for not including Braille accepted
<Sprejeta je utemeljitev, da Braillova pisava ni potrebna.>
Justification for not including Braille accepted
<Sprejeta je utemeljitev, da Braillova pisava ni potrebna>
Justification for not including Braille accepted
<Sprejeta je utemeljitev, zakaj niso vključeni podatki v Braillovi pisavi>
Justification for not including Braille accepted
Odobrena razlaga, da Braillova pisava ni potrebna.
Justification for not including Braille accepted
Razlog za nedostopnost v Braillovi pisavi zaveden.
Justification for not including Braille accepted
Sprejeta obrazložitev glede neuporabe Braillove pisave.
Justification for not including Braille accepted 100 x 1 tablets
Odobrena razlaga, da Braillova pisava ni potrebna 100 x 1 tableta
Justification for not including Braille accepted.
Sprejeta je utemeljitev, zakaj niso vključeni podatki v Braillovi pisavi.
Justification for not including Braille accepted.
Sprejeta obrazložitev glede neuporabe Braillove pisave.
Justification for not including Braille accepted17.
Sprejeta je utemeljitev, da Braillova pisava ni potrebna.
Justification for not including Braille is accepted
Sprejeta je utemeljitev, da Braillova pisava ni potrebna
Juvenile Animal Studies
Študije na mladičih živali
Juvenile Animals
Mlade živali
Juvenile Idiopathic Arthritis Paediatric population
Juvenilni idiopatski artritis Pediatrična populacija
Juvenile idiopathic arthritis, psoriatic arthritis and ankylosing spondylitis
Juvenilni idiopatski artritis, psoriatični artritis in ankilozirajoči spondilitis
Juvenile Myoclonic Epilepsy. in the treatment of primary generalised tonic-clonic seizures in adults and adolescents from 12 years of age with Idiopathic Generalised Epilepsy.
miokloničnih napadov pri odraslih in mladostnikih od 12. leta starosti z juvenilno mioklonično epilepsijo primarno generaliziranih tonično-kloničnih napadov pri odraslih in mladostnikih od 12. leta starosti z idiopatsko generalizirano epilepsijo
Juvenile rats (comparable to a >2 year old pediatric population) administered cabozantinib showed increased WBC parameters, decreased haematopoiesis, pubescent/immature female reproductive system (without delayed vaginal opening), tooth abnormalities, reduced bone mineral content and density, liver pigmentation and lymph node lymphoid hyperplasia.
Pri mladih podganah (primerljivo z > 2-letno pediatrično populacijo), ki so dobivale kabozantinib, so se pokazali zvišani parametri belih krvnih celic, znižana hematopoeza, pubertetni/nezrel ženski reprodukcijski sistem (brez zakasnitve odpiranja nožnice), nenormalnosti zobovja, zmanjšana mineralna vsebnost in gostota kosti, pigmentacija jeter in hiperplazija žolčevoda.
Juvenile rats (correlating to a <2 year pediatric population) showed similar treatment-related findings, but appeared to be more sensitive to cabozantinib-related toxicity at comparable dose levels.
Ocenitve mladih podgan (primerljivo z < 2-letno pediatrično populacijo) so pokazale podobne izsledke za zdravljenje, vendar kaže, da je občutljivost za toksičnost zaradi kabozantiniba pri primerljivih ravneh odmerkov večja.
Juvenile Toxicity
Toksičnost za mladiče
Järvevana tee 9 EE-11314 Tallinn
Järvevana tee 9
k 48 weeks of double-blind adefovir dipivoxil followed by 192 weeks open-label tenofovir disoproxil fumarate. l Figures presented are cumulative percentages based upon a Kaplan Meier analysis excluding data collected after the addition of emtricitabine to open-label tenofovir disoproxil fumarate (KM-TDF).
k 48-tedensko dvojno slepo zdravljenje z dipivoksiladefoviratom, ki mu sledi 192-tedensko odprto zdravljenje z dizoproksiltenofovirijevim fumaratom. l Prikazane številke so kumulativni odstotki na podlagi Kaplan-Meierjeve analize, brez podatkov zbranih po dodajanju emtricitabina k odprtemu zdravljenju z dizoproksiltenofovirijevim fumaratom (KM–TDF).
k e.g. vaginal haemorrhage, haematospermia, postmenopausal haemorrhage l e.g. contusion, traumatic haematoma, traumatic haemorrhage
k npr. krvavitev iz nožnice, hematospermija, pomenopavzalna krvavitev l npr. kontuzija, travmatski hematom, travmatska krvavitev
k including rash macular, rash papular, rash maculopapular l developed in a hepatitis C antibody-positive patient 12 days after a dose of BeneFIX for a bleeding episode.
k vključno z makuloznim izpuščajem, papuloznim izpuščajem, makulopapuloznim izpuščajem l pojavil se je pri bolniku, pozitivnem na protitelesa proti hepatitisu C, 12 dni po odmerku zdravila BeneFIX zaradi epizode krvavitve.
K-M at Year 1, % (95% CI)
K-M po 1 letu,
K-M at Year 2, % (95% CI)
K-M po 1 letu,
K-M at Year 2, % (95% CI)
K-M po dveh letih, % (95 % IZ)
K-M estimate of OS at 24 monthsb % (95% CI)
K-M ocena OS pri 24 mesecihb, % (95 % IZ)
K-M median (95% Confidence Interval)
Mediana vrednost K-M (95
K65R was absent and L74V and Y115F were uncommon (3 %).
K65R ni bila prisotna, L74V in Y115F pa sta bili občasni ( 3 %).
K65R was absent and L74V and Y115F were uncommon (3%).
K65R ni bila prisotna, L74V in Y115F pa sta bili občasni ( 3 %).
K65R, K70E, M184V, and M184I) that potentially confer resistance to tenofovir or emtricitabine.
K65R, K70E, M184V in M184I), ki bi lahko povzročile rezistenco na tenofovir ali emtricitabin.
Kadcyla 100 mg powder for concentrate for solution for infusion trastuzumab emtansine
Kadcyla 100 mg prašek za koncentrat za raztopino za infundiranje trastuzumab emtanzin
Kadcyla 100mg: using a sterile syringe, slowly inject 5 mL of sterile water for injection into the 100 mg trastuzumab emtansine vial.
Kadcyla 100 mg: s sterilno injekcijsko brizgo počasi injicirajte 5 ml sterilne vode za injekcije v 100-mg vialo trastuzumaba emtanzina.
Kadcyla 160 mg powder for concentrate for solution for infusion trastuzumab emtansine
Kadcyla 160 mg prašek za koncentrat za raztopino za infundiranje trastuzumab emtanzin
Kadcyla 160mg: using a sterile syringe, slowly inject 8 mL of sterile water for injection into the 160 mg trastuzumab emtansine vial.
Kadcyla 160 mg: s sterilno injekcijsko brizgo počasi injicirajte 8 ml sterilne vode za injekcije v 160-mg vialo trastuzumaba emtanzina.
Kadcyla and Herceptin are two very different products with different active substances never to be used interchangeably.
Zdravili Kadcyla in Herceptin sta dve različni zdravili z različnima zdravilnima učinkovinama, ki se nikoli ne smeta uporabljati izmenljivo.
Kadcyla can only be used when the cancer has been shown to ‘overexpress HER2’: this means that the cancer cell produces on its surface large quantities of a protein which stimulates the growth of the cancer cell and is called HER2 (human epidermal growth factor).
Uporablja se lahko samo, kadar se ugotovi, da rak „čezmerno izraža HER2“: to pomeni, da na površini rakave celice nastajajo velike količine beljakovine, ki spodbuja rast rakave celice, in se imenuje HER2 (humani epidermalni rastni dejavnik).
Kadcyla contains the active substance trastuzumab emtansine, which is made up of two parts that are linked together: trastuzumab - a monoclonal antibody that binds selectively to an antigen (a target protein) called human epidermal growth factor receptor 2 (HER2).
Zdravilo Kadcyla vsebuje zdravilno učinkovino trastuzumab emtanzin; učinkovina je sestavljena iz dveh med seboj povezanih delov: trastuzumaba – to je monoklonsko protitelo, ki se selektivno veže na antigen (tarčno beljakovino), ki se imenuje humani receptor za epidermalni rastni dejavnik 2 (HER2).
Kadcyla dose should not be re-escalated after a dose reduction is made.
Odmerka zdravila Kadcyla se po zmanjšanju ne sme več povečati.
Kadcyla is a white to off-white lyophilised powder for concentrate for solution for infusion supplied in glass vials.
Zdravilo Kadcyla je bel ali skoraj bel liofiliziran prašek za koncentrat za raztopino za infundiranje v steklenih vialah.
Kadcyla is an antibody-drug conjugate containing humanized anti-HER2 IgG1 antibody trastuzumab and DM1, a microtubule-inhibitory maytansinoid.
Zdravilo Kadcyla je konjugat med protitelesom in zdravilom, ki vsebuje humanizirano anti- HER2 IgG1 protitelo trastuzumab in DM1, zaviralec mikrotubulov (majtanzinski derivat).
Kadcyla is available in packs containing 1 vial.
Zdravilo Kadcyla je na voljo v pakiranjih z 1 vialo.
Kadcyla is NOT a generic version of Herceptin and has different properties, indications and dose.
Zdravilo Kadcyla NI generična različica zdravila Herceptin in ima različne lastnosti, indikacije in uporabo.
Kadcyla is provided in 15 ml (100 mg) or 20 ml (160 mg) Type 1 glass vial closed with a grey-butyl rubber stopper coated with fluoro-resin laminate, and sealed with an aluminium seal with a white or purple plastic flip-off cap.
Zdravilo Kadcyla je na voljo v 15-ml (100 mg) in 20-ml (160 mg) vialah iz stekla tipa 1, ki imajo zamašek iz sive butilne gume, prekrit s fluorosmolnim laminatom, in so zapečatene z aluminijsko zaporo z belo ali vijoličasto plastično snemno zaporko.
Kadcyla is used to treat breast cancer in adults when: the cancer cells have many HER2 proteins on them - your doctor will test your cancer cells for this.
Zdravilo Kadcyla uporabljamo za zdravljenje raka dojk pri odraslih: če imajo rakave celice na svoji površini veliko beljakovine HER2 – zdravnik bo zato opravil preiskavo vaših rakavih celic,
Kadcyla should only be prescribed by a physician and administered under the supervision of a healthcare professional who is experienced in the treatment of cancer patients.
Zdravilo Kadcyla sme predpisati le zdravnik in se ga sme uporabiti le pod nadzorom zdravnika, ki ima izkušnje z zdravljenjem onkoloških bolnikov.
Kadcyla will be given to you by a doctor or nurse in a hospital or clinic:
Zdravilo Kadcyla vam bo dal zdravnik ali medicinska sestra v bolnišnici ali ambulanti:
Kadcyla, as a single agent, is indicated for the treatment of adult patients with HER2-positive, unresectable locally advanced or metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination.
Zdravilo Kadcyla je kot monoterapija indicirano za zdravljenje odraslih bolnikov s HER2-pozitivnim, neoperabilnim, lokalno napredovalim ali metastatskim rakom dojk, predhodno zdravljenih s trastuzumabom in taksanom, samostojno ali v kombinaciji.
Kadcyla100 mg powder for concentrate for solution for infusion Kadcyla 160 mg powder for concentrate for solution for infusion trastuzumab emtansine
Kadcyla 100 mg prašek za koncentrat za raztopino za infundiranje Kadcyla 160 mg prašek za koncentrat za raztopino za infundiranje trastuzumab emtanzin
Kaiser-Wilhelm-Allee 51368 Leverkusen Germany
Bayer Pharma AG Keiser-Wilhelm Allee 51368 Leverkusen Nemčija
Kaletra 100 mg/25 mg film-coated tablets are supplied in plastic bottles containing 60 tablets.
Filmsko obložene tablete Kaletra z jakostjo 100mg/20mg so na voljo v plastenkah, ki vsebujejo 60 tablet.
Kaletra 100/25 mg tablet twice-daily weight-band dosing without nevirapine have been studied in a total of 53 paediatric patients.
100/25 mg tablete dvakrat na dan z odmerjanjem glede na telesno maso brez nevirapina so raziskali pri skupaj 53 pediatričnih bolnikih.
Kaletra 400/100 mg + ritonavir 300 mg) twice daily has allowed compensating for the CYP 3A4 inducer effect of rifampicin.
Kaletra 400/100 mg + ritonavir 300 mg) dvakrat na dan je omogočila kompenzacijo indukcijskega učinka rifampicina na CYP3A4.
Kaletra 800/200 mg was administered in combination with emtricitabine 200 mg and tenofovir DF 300 mg as part of a once-daily regimen.
Zdravilo Kaletra 800/200 mg so uporabljali v kombinaciji z emtricitabinom 200 mg in tenofovirjem DF 300 mg kot del sheme enkrat na dan.
Kaletra and starting lamotrigine:
Kaletra in pričnejo z uporabo
Kaletra and starting lamotrigine:
zdravilom Kaletra, je
Kaletra contains 42% v/v alcohol and 15% propylene glycol w/v.
Zdravilo Kaletra vsebuje 42% v/v alkohola in 15 % m/v propilenglikola.
Kaletra contains 42% v/v alcohol.
Zdravilo Kaletra vsebuje 42% v/v alkohola.
Kaletra contains potassium as acesulfame potassium, which may be harmful to people on a low potassium diet.
Zdravilo Kaletra vsebuje kalij v obliki kalijevega acesulfamata, kar lahko škoduje ljudem na dieti z malo kalija.
Kaletra contains the active substances lopinavir and ritonavir.
Zdravilo Kaletra vsebuje zdravilni učinkovini lopinavir in ritonavir.
Kaletra does not cure HIV infection or AIDS, but it may delay the damage to the immune system, and the development of infections and diseases associated with AIDS.
Zdravilo Kaletra ne ozdravi okužbe z virusom HIV ali aidsa, vendar pa lahko upočasni slabšanje imunskega sistema in razvoj okužb in bolezni, povezanih z aidsom.
Kaletra does not inhibit CYP2D6, CYP2C9, CYP2C19, CYP2E1, CYP2B6 or CYP1A2 at clinically relevant concentrations (see section 4.3).
Zdravilo Kaletra v klinično pomembnih koncentracijah ne zavira CYP2D6, CYP2C9, CYP2C19, CYP2E1, CYP2B6 ali CYP1A2 (glejte poglavje 4.3).
Kaletra does not reduce the risk of passing HIV to others.
Zdravilo Kaletra ne zmanjša tveganja za prenos HIV na druge.
Kaletra does this by slowing down the spread of the infection in your body.
Kaletra to doseže tako, da upočasni širjenje okužbe v telesu.
Kaletra film-coated tablets are pale yellow debossed with [Abbott logo] and “KC”.
Filmsko obložene tablete Kaletra so bledo rumene in imajo vtisnjeni oznaki [Abbottov logo] in "KC".
Kaletra film-coated tablets are yellow embossed with [Abbott logo] and “KA”.
Filmsko obložene tablete zdravila Kaletra so rumene in imajo vtisnjeni oznaki [Abbottov logo] in "KA".
Kaletra has been shown in vivo to induce its own metabolism and to increase the biotransformation of some medicinal products metabolised by cytochrome P450 enzymes (including CYP2C9 and CYP2C19) and by glucuronidation.
In vivo je bilo dokazano, da zdravilo Kaletra inducira svojo lastno presnovo in zvečuje biotransformacijo nekaterih zdravil, ki se presnavljajo z encimi citokroma P450 (vključno s CYP2C9 in CYP2C19) in z glukuronidacijo.
Kaletra is a medicine that contains two active substances, lopinavir and ritonavir.
Kaletra je zdravilo, ki vsebuje dve zdravilni učinkovini, lopinavir in ritonavir.
Kaletra is administered orally and should always be taken with food (see section 5.2)
Zdravilo Kaletra se jemlje peroralno in vedno s hrano (glejte poglavje 5.2).
Kaletra is contraindicated in patients with severe liver impairment (see section 4.3).
Zdravilo Kaletra je kontraindicirana pri bolnikih s hudo okvaro jeter (glejte poglavje 4.3).
Kaletra is not a cure for HIV infection or AIDS.
Zdravilo Kaletra ne ozdravi okužbe s HIV ali AIDS-a.
Kaletra is prescribed for use in combination with other antiviral medicines.
Zdravilo Kaletra se uporablja v kombinaciji z drugimi protivirusnimi zdravili.
Kaletra is recommended for use in adults and children 2 years of age or older who are infected with HIV.
Zdravilo Kaletra je priporočeno za uporabo pri odraslih in otrocih od 2. leta dalje, okuženih s HIV.
Kaletra is required.
zdravilom Kaletra, je
Kaletra is used by children 2 years of age or older, adolescents and adults who are infected with HIV, the virus which causes AIDS.
Zdravilo Kaletra se uporablja pri otrocih, starih 2 leti ali več, mladostnikih in odraslih, okuženih s HIV, virusom, ki povzroča AIDS.
Kaletra is used together with other anti-HIV medicines to treat patients over two years of age who are infected with human immunodeficiency virus type 1 (HIV-1), a virus that causes acquired immune deficiency syndrome (AIDS).
Zdravilo Kaletra se uporablja skupaj z drugimi zdravili za zdravljenje okužbe z virusom HIV pri bolnikih, starejših od dveh let, ki so okuženi z virusom humane imunske pomanjkljivosti tipa 1 (HIV-1), tj. virusom, ki povzroča sindrom pridobljene imunske pomanjkljivosti (aids).
Kaletra must not be
zdravila Kaletra je priporočljiv
Kaletra must not be administered
Zdravila Kaletra se ne sme
Kaletra must not be administered once daily in combination with amprenavir.
Zdravila Kaletra se ne sme uporabljati enkrat na dan v kombinaciji z amprenavirejm.
Kaletra must not be administered once daily in combination with nevirapine.
uporabljati enkrat na dan v
Kaletra must not be co-administered with oral midazolam (see section 4.3), whereas caution should be used with co-administration of Kaletra and parenteral midazolam.
Zdravila Kaletra se ne sme uporabljati sočasno s peroralnim midazolamom (glejte poglavje 4.3), v primeru sočasne uporabe zdravila Kaletra in parenteralnega midazolama pa je potrebna previdnost.
Kaletra must not be taken once daily with efavirenz, nevirapine, carbamazepine, phenobarbital and phenytoin.
V primeru uporabe enkrat na dan se zdravila Kaletra ne sme jemati z efavirenzem, nevirapinom, karbamazepinom, fenobarbitalom ali fenitoinom.
Kaletra must not be used by patients with severe liver disease or by patients who are taking St John’s wort (a herbal preparation used to treat depression) or medicines that are broken down in the same way as Kaletra and are harmful at high levels in the blood.
Zdravila Kaletra ne smejo uporabljati bolniki z resnim obolenjem jeter ali tisti, ki se zdravijo s šentjanževko (rastlinskim pripravkom za zdravljenje depresije) ali zdravili, ki se presnavljajo enako kot zdravilo Kaletra in so pri visokih koncentracijah v krvi škodljiva.
Kaletra must not be used in people who are hypersensitive (allergic) to lopinavir, ritonavir or any of the other ingredients.
Zdravila Kaletra ne smejo uporabljati osebe, ki so preobčutljive za (alergične na) lopinavir, ritonavir ali katero koli drugo sestavino zdravila.
Kaletra oral solution comes in a multiple-dose 60 ml amber bottle.
Zdravilo Kaletra peroralna raztopina je na voljo v 60-ml plastenkah za večkratno odmerjanje, ki so jantarne barve.
Kaletra oral solution contains approximately 42% v/v alcohol.
Peroralna raztopina zdravila Kaletra vsebuje približno 42% v/v alkohola.
Kaletra oral solution is contraindicated in children below the age of 2 years, pregnant women, patients with hepatic or renal failure and patients treated with disulfiram or metronidazole due to the potential risk of toxicity from the excipient propylene glycol (see section 4.4).
Zaradi možnih toksičnih učinkov pomožne snovi propilenglikola je peroralna raztopina zdravila Kaletra kontraindicirana pri otrocih, mlajših od 2 let, nosečnicah, bolnikih z odpovedjo jeter ali ledvic in pri bolnikih, zdravljenih z disulfiramom ali metronidazolom (glejte poglavje 4.4).
Kaletra pharmacokinetics have not been studied in older people.
Farmakokinetika zdravila Kaletra pri starejših ljudeh ni raziskana.
Kaletra should always be taken every day to help control your HIV infection, no matter how much better you feel.
Da bo zdravilo Kaletra pomagala obvladovati okužbo s HIV, jo morate vzeti vsak dan dvakrat, ne glede na to, koliko bolje se počutite.
Kaletra should always be taken every day to help control your HIV infection, no matter how much better you feel.
Da bo zdravilo Kaletra pomagalo obvladovati okužbo s HIV, jo morate vzeti vsak dan, ne glede na to, koliko bolje se počutite.
Kaletra should always be taken twice every day to help control your HIV infection, no matter how much better you feel.
Da bo zdravilo Kaletra pomagala obvladovati okužbo s HIV, jo morate vzeti vsak dan dvakrat, ne glede na to, koliko bolje se počutite.
Kaletra tablets are administered orally and must be swallowed whole and not chewed, broken or crushed.
Tablete Kaletra se uporabljajo peroralno in jih je treba pogoltniti cele; ne sme se jih gristi, lomiti ali drobiti.
Kaletra tablets can be taken with or without food.
Lahko se jemljejo s hrano ali brez nje.
Kaletra tablets can be taken with or without food.
Zdravilo Kaletra tablete se lahko jemlje s hrano ali brez nje.
Kaletra tablets can be taken with or without food.
Zdravilo Kaletra tablete se lahko jemljejo s harno ali brez nje.
Kaletra with colchicine in patients
je kontraindicirana pri bolnikih z
Kalydeco 150 mg film-coated tablets
Kalydeco 150 mg filmsko obložene tablete
Kalydeco 150 mg film-coated tablets
Kalydeco 150 mg filmsko obložene tablete ivakaftor
Kalydeco 150 mg film-coated tablets ivacaftor
Kalydeco 150 mg filmsko obložene tablete ivakaftor
Kalydeco 150 mg tablets ivacaftor
Možni pomen teh ugotovitev za ljudi ni znan.
Kalydeco 50 mg granules in sachet ivacaftor
Kalydeco 50 mg zrnca v vrečici ivakaftor
Kalydeco 50 mg granules in sachet Kalydeco 75 mg granules in sachet Ivacaftor
Kalydeco 50 mg zrnca v vrečici Kalydeco 75 mg zrnca v vrečici ivakaftor
Kalydeco 50 mg granules in sachet: The active substance is ivacaftor.
Kalydeco 50 mg zrnca v vrečici: zdravilna učinkovina je ivakaftor.
Kalydeco 50 mg granules ivacaftor
Kalydeco 50 mg zrnca v vrečici ivakaftor
Kalydeco 75 mg granules
Kalydeco 75 mg zrnca
Kalydeco 75 mg granules in sachet ivacaftor
Kalydeco 75 mg zrnca v vrečici ivakaftor
Kalydeco 75 mg granules in sachet: The active substance is ivacaftor.
Kalydeco 75 mg zrnca v vrečici: zdravilna učinkovina je ivakaftor.
Kalydeco can also affect how some other medicines work.
Tudi zdravilo Kalydeco lahko vpliva na delovanje nekaterih drugih zdravil.
Kalydeco can make your child dizzy.
Zaradi zdravila Kalydeco lahko otrok postane omotičen.
Kalydeco contains lactose
Zdravilo Kalydeco vsebuje laktozo
Kalydeco contains lactose.
9240 (3420)
Kalydeco contains the active ingredient ivacaftor.
Zdravilo Kalydeco vsebuje zdravilno učinkovino ivakaftor.
Kalydeco granules are indicated for the treatment of children with cystic fibrosis (CF) aged 2 years and older and weighing less than 25 kg who have one of the following gating mutations in the CFTR gene: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R.
Zrnca Kalydeco so namenjena zdravljenju otrok s cistično fibrozo (CF), starih 2 leti in starejših, ki tehtajo manj kot 25 kg in imajo eno od naslednjih mutacij spreminjanja prehodnosti kanalčkov celične membrane na genu CFTR (cystic fibrosis transmembrane conductance regulator): G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N ali S549R.